Lindvall O
Dept of Neurology, University Hospital, Lund, Sweden.
Trends Neurosci. 1991 Aug;14(8):376-84. doi: 10.1016/0166-2236(91)90167-s.
Over the past decade experimental data obtained from animals have suggested that restoration or preservation of function through cell transplantation into the CNS might be developed into a useful therapeutic approach in human neurodegenerative disorders. Clinical trials in patients with Parkinson's disease have provided evidence that grafts of fetal dopaminergic neurons can survive and induce functional effects in the human brain, but no treatment based on transplantation is available yet. Initiation of studies of patients with striatal neural grafts in Huntington's disease is supported by findings in animal models, and is motivated by the lack of therapy and the severity of the symptoms in this disorder. Application of cell transplantation to other neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, and hereditary ataxia is definitely premature. Further progress can be made only by systematic studies in animals of the scientific issues that can now be defined, but will also require clinical trials in a few well-monitored patients.
在过去十年中，从动物实验获得的数据表明，通过将细胞移植到中枢神经系统来恢复或保留功能，可能会发展成为一种治疗人类神经退行性疾病的有效方法。帕金森病患者的临床试验已经证明，胎儿多巴胺能神经元移植可以在人脑中存活并产生功能效应，但目前尚无基于移植的治疗方法。动物模型的研究结果支持了对亨廷顿病患者进行纹状体神经移植研究的启动，而这种疾病缺乏有效治疗方法且症状严重，这推动了该研究的开展。将细胞移植应用于其他神经退行性疾病，如阿尔茨海默病、肌萎缩侧索硬化症和遗传性共济失调，目前肯定还为时过早。只有通过对现在能够明确的科学问题进行系统的动物研究，才能取得进一步进展，但这也需要在少数经过严密监测的患者身上进行临床试验。
